Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down to $13.56

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) gapped down before the market opened on Monday . The stock had previously closed at $13.56, but opened at $11.08. Neumora Therapeutics shares last traded at $11.39, with a volume of 381,439 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on NMRA shares. Royal Bank of Canada restated an “outperform” rating and set a $31.00 price target on shares of Neumora Therapeutics in a research note on Thursday, March 28th. William Blair reiterated an “outperform” rating on shares of Neumora Therapeutics in a research note on Friday, April 12th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.57.

Neumora Therapeutics Stock Down 2.1 %

The company’s fifty day simple moving average is $15.96 and its 200 day simple moving average is $14.20.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.05. On average, equities research analysts anticipate that Neumora Therapeutics, Inc. will post -1.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NMRA. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST bought a new position in Neumora Therapeutics in the 3rd quarter valued at $46,692,000. Citigroup Inc. bought a new stake in shares of Neumora Therapeutics during the 3rd quarter worth $203,000. Johnson & Johnson bought a new stake in shares of Neumora Therapeutics during the 3rd quarter worth $12,870,000. FMR LLC bought a new stake in shares of Neumora Therapeutics during the 3rd quarter worth $79,360,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Neumora Therapeutics during the 3rd quarter worth $302,000. 47.65% of the stock is owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.